💸 The Tape

As federal rescheduling reshapes the domestic landscape and international medical cannabis markets expand rapidly across Germany, the UK, Australia, Poland, and beyond, the certification that separates contenders from pretenders in the global supply chain is European Union Good Manufacturing Practice compliance. It's the gold standard for pharmaceutical-grade cannabis production — and for American operators eyeing international revenue streams, understanding what it takes to earn and maintain it isn't optional. It's existential.

What EU GMP Actually Means

EU GMP certification is a regulatory framework governed by the European Medicines Agency (EMA) and enforced by national competent authorities — such as Germany's Federal Institute for Drugs and Medical Devices (BfArM) — that establishes the minimum standards a manufacturer must meet to produce pharmaceutical products for European markets. It covers every dimension of production: facility design, environmental controls, personnel qualifications, documentation, quality assurance, batch testing, supply chain integrity, and post-market surveillance.

For cannabis specifically, EU GMP certification means a cultivation or processing facility has demonstrated that it can consistently produce pharmaceutical-grade product — flower, extracts, or API — to the same standards applied to conventional pharmaceutical manufacturing. Every batch must be reproducible. Every process must be documented. Every deviation must be investigated, recorded, and resolved.

This isn't a checkbox exercise. It's a complete operational philosophy.

The Qualification Process

Earning EU GMP certification is a multi-year undertaking that typically unfolds across several phases.

It begins with facility design and buildout. The physical infrastructure must meet pharmaceutical-grade specifications from the ground up — or be retrofitted to comply. That includes cleanroom environments with defined air handling and particulate controls, segregated production zones to prevent cross-contamination, dedicated quality control laboratories, and validated environmental monitoring systems. HVAC, water purification, and waste management systems all require qualification protocols — Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) — before a single plant touches the facility.

Next comes the quality management system (QMS). EU GMP requires a fully documented QMS covering standard operating procedures (SOPs) for every process, from seed selection through final packaging. This includes batch production records, deviation and corrective action protocols (CAPA systems), change control procedures, supplier qualification programs, and stability testing regimes. The documentation burden alone can overwhelm organizations that aren't accustomed to pharmaceutical-level record-keeping.

Personnel qualifications are equally rigorous. EU GMP mandates a Qualified Person (QP) — an individual with specific academic credentials and professional experience in pharmaceutical manufacturing — who is personally responsible for certifying that each batch meets specifications before release. The QP role carries legal liability in many European jurisdictions, and finding qualified individuals with cannabis-specific experience remains a significant bottleneck.

Once the facility, systems, and personnel are in place, the operation must undergo a formal inspection by the relevant national authority — often involving multi-day site visits by regulatory auditors who examine everything from raw material intake procedures to finished product release protocols. Successful inspection results in a GMP certificate and listing in the EudraGMDP database, which European regulators and importers use to verify compliance.

The entire process — from initial gap assessment to certified production — typically takes 18 to 36 months and can cost millions of dollars in facility upgrades, consulting fees, personnel, and validation work.

GACP: The On-Ramp

For operators not ready to commit to the full EU GMP journey, Good Agricultural and Collection Practices (GACP) certification offers a viable — and increasingly important — entry point into international markets.

GACP governs the cultivation and harvesting phase of cannabis production, establishing standards for growing conditions, pest management, harvesting procedures, drying, trimming, and initial post-harvest handling. It's the upstream complement to EU GMP, which covers processing, manufacturing, and distribution.

Here's where the distinction matters commercially: many international supply chains are structured so that GACP-certified cultivators supply raw material to EU GMP-certified processors who handle extraction, formulation, and packaging for distribution. This division of labor allows cultivation-focused operators to participate in international medical markets without building out full pharmaceutical manufacturing infrastructure.

Companies like Decibel Cannabis have leveraged this model effectively, onboarding 40+ GACP-certified cultivators into their supply network to feed EU GMP processing operations. For smaller or mid-sized operators, GACP certification represents a realistic path to international revenue — provided they can meet the quality and consistency standards that EU GMP processors require from their raw material suppliers.

GACP certification is faster and less capital-intensive than EU GMP, but it's not a participation trophy. Audits assess traceability systems, contamination controls, documentation practices, and the ability to produce consistent, specification-compliant biomass. Operators who treat GACP as merely a stepping stone rather than a rigorous standard in its own right will find themselves locked out of supply agreements with the EU GMP processors who ultimately control market access.

Maintaining the Standard

Earning EU GMP certification is hard. Keeping it may be harder.

Facilities are subject to periodic re-inspection — typically every two to three years — by national authorities, with the possibility of unannounced inspections at any time. Between formal audits, operators must maintain continuous compliance through internal audit programs, ongoing training, environmental monitoring, and regular review of quality metrics.

Any significant change to the facility, process, equipment, or supply chain triggers a change control procedure that must be documented, risk-assessed, and in some cases pre-approved by regulators. New cultivars, new extraction methods, new packaging formats — all require formal validation before entering commercial production.

The cost of maintaining EU GMP compliance is substantial and ongoing. Quality assurance teams, laboratory operations, stability testing programs, and regulatory affairs functions all represent permanent overhead. For cannabis companies accustomed to lean startup structures, the transition to pharmaceutical-grade operations requires a fundamental rethinking of organizational design and cost structure.

What This Means for U.S. MSOs

For the largest American operators — Curaleaf, Trulieve, Green Thumb, Verano — the path to international markets runs directly through EU GMP. And the rescheduling of medical cannabis to Schedule III makes that path more relevant than ever.

With the DEA now establishing a federal registration framework for medical cannabis operations, U.S. operators are entering an era where pharmaceutical-grade compliance isn't just an international aspiration — it's becoming a domestic expectation. Companies that invest in EU GMP or GACP certification now are building infrastructure that serves both international expansion and the evolving U.S. regulatory environment.

Some MSOs are already moving. Curaleaf's full acquisition of Four 20 Pharma in Germany gives it an EU GMP-certified platform in Europe's largest medical market. Aurora Cannabis recently acquired Safari Flower Company specifically for its EU GMP-certified facility in Ontario. Organigram's acquisition of Sanity Group provides a multi-country European footprint with established regulatory credentials.

For operators that haven't yet made international moves, the window is narrowing. European markets are consolidating around established suppliers with proven compliance track records. Building EU GMP capability from scratch takes years. Acquiring it is faster but increasingly expensive as the number of certified facilities with available capacity shrinks.

The Bottom Line

EU GMP certification isn't a marketing badge — it's a market access requirement. As international medical cannabis demand accelerates and U.S. federal policy aligns more closely with pharmaceutical regulation, the operators who invested in pharmaceutical-grade infrastructure early will own the supply chains that matter.

The rest will be watching from the outside.

📈 Dog Walkers

$CNTMF ( ▼ 8.97% ) Divests Texas

FLUENT Corp. is shedding assets — and this time it's Texas.

The vertically integrated cannabis company announced a definitive agreement to sell 100% of its Texas subsidiary, Cansortium Texas, to Legacy Therapeutics for $30 million. The deal includes FLUENT's Texas license, cultivation, manufacturing, and delivery operations in Schulenburg, as well as its Houston retail business. Payment is structured as $25 million at closing with two additional $2.5 million installments on the first and second anniversaries.

The move fits squarely into FLUENT's broader strategy of streamlining operations ahead of its pending all-stock acquisition by Vireo Growth, announced earlier this week. FLUENT's board had already approved an operating budget designed to divest non-core assets and optimize the business before the Vireo transaction closes. Texas, with its highly restrictive Compassionate Use Program and limited commercial upside relative to other markets, appears to have been identified as exactly the kind of asset better suited to a different operator's playbook.

Proceeds will primarily go toward paying down FLUENT's senior secured debt — a balance sheet cleanup that directly benefits the combined entity Vireo will eventually inherit.

The buyer is notable in its own right. Legacy Therapeutics is led by Randy J. Mire, Pharm.D, who describes himself as "the first pharmacist in the south to dispense medical marijuana." His pharmaceutical background and patient-access focus suggest Legacy intends to run the Texas operation with a clinical, compliance-first approach — a natural fit for a medical-only market.

Interim CEO David Vautrin expressed confidence in Legacy's ability to grow the platform FLUENT built for Texas Compassionate Use patients.

For FLUENT, the Texas exit is another piece of the pre-closing puzzle — simplifying the business, reducing debt, and preparing a cleaner package for its new home inside Vireo.

HHC Finds Itself On S1

The DEA is making it official: HHC is getting its own line item on the federal controlled substances list — and the agency wants everyone to know it was already illegal.

A final rule scheduled for publication Monday in the Federal Register establishes a separate Schedule I listing for hexahydrocannabinol (HHC) under the new DEA drug code 7220. The agency emphasized this is an administrative action, not a change in legal status — HHC has been controlled under drug code 7370 as a tetrahydrocannabinol since it first hit the market.

The practical effect is bureaucratic but meaningful: the dedicated listing allows the DEA to establish aggregate production quotas and grant manufacturing and procurement quotas to registered manufacturers — regulatory tools that require a substance-specific code.

More significant is the DEA's explicit position on sourcing. The agency stated that HHC is a synthetic substance, and that the 2018 Farm Bill's exemption for "tetrahydrocannabinols in hemp" applies only to those naturally occurring in the cannabis plant. THC compounds produced through chemical conversion — even from hemp-derived starting material — are not exempt and remain Schedule I.

That interpretation puts the DEA squarely at odds with the hemp industry's long-held argument that chemically converted cannabinoids derived from legal hemp fall under the Farm Bill's protections.

The rule follows a June 2025 UN notification adding HHC to the 1971 Convention on Psychotropic Substances. HHS confirmed there are no approved or investigational drug applications for the compound and agreed with the listing.

No public comment period. Effective immediately upon publication.

🗞️ The News

📺 YouTube

From Policy To Execution: Cannabis Turns The Corner | TTB Weekly Recap

✅ In this week’s Trade To Black Weekly Recap presented by FRE Pouch, Shadd Dales breaks down the shift from cannabis policy to real-world execution.

The DEA has officially opened its registration portal for medical cannabis operators—meaning companies now have a 60-day window to apply for federal recognition. This follows last week’s move to Schedule III and marks the first real step in turning policy into action.

From a financial standpoint, the biggest impact is 280E. For years, operators have been taxed at extreme rates, limiting profitability and growth. That now starts to unwind on the medical side—and for major U.S. operators, that changes everything.